Femasys Inc. (NASDAQ:FEMY) Short Interest Up 64.2% in August

Posted by Brenda Bartman on Sep 1st, 2026

Femasys Inc. (NASDAQ:FEMY – Get Free Report) saw a large growth in short interest in August. As of August 14th, there was short interest totaling 434,999 shares, a growth of 64.2% from the July 30th total of 264,928 shares. Based on an average daily trading volume, of 274,553 shares, the short-interest ratio is presently 1.6 days. Currently, 5.6% of the company’s stock are sold short.

Analyst Ratings Changes

A number of equities analysts recently commented on FEMY shares. Maxim Group reduced their price objective on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wall Street Zen lowered Femasys from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Lake Street Capital lowered their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Finally, Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.00.

View Our Latest Report on Femasys

Insider Activity

In other Femasys news, CEO Kathy Lee-Sepsick purchased 15,625 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dov Elefant purchased 15,625 shares of the stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief financial officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 38,750 shares of company stock worth $124,000 over the last ninety days. 7.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Femasys

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers acquired a new position in shares of Femasys in the 4th quarter worth approximately $36,000. Kovack Advisors Inc. purchased a new stake in Femasys in the fourth quarter valued at approximately $27,000. State Street Corp raised its position in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the period. Jane Street Group LLC acquired a new position in Femasys during the fourth quarter worth $62,000. Finally, HRT Financial LP purchased a new position in shares of Femasys during the fourth quarter worth $30,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Trading Down 5.0%

NASDAQ:FEMY traded down $0.17 on Tuesday, reaching $3.26. The company’s stock had a trading volume of 66,804 shares, compared to its average volume of 300,893. Femasys has a 12-month low of $2.02 and a 12-month high of $22.20. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The firm has a market cap of $27.32 million, a price-to-earnings ratio of -0.92 and a beta of -2.08. The stock has a 50 day moving average price of $3.24 and a 200 day moving average price of $6.67.

Femasys (NASDAQ:FEMY – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Femasys Company Profile

(Get Free Report)

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.